WELCOME TO The PHARMACEUTICAL REPORT
Leveraging Predictive Analytics for Pharmaceutical Innovation
March 20, 2019
I'm For Real
Enter your details once to access all our information and resources
Fera is a specialty pharmaceutical company interested in acquiring and licensing ANDAs and NDAs, pursuing its own product development and partnering with companies in need of commercialization and marketing support.
whitePaper | May 22, 2021
One of the key roles of the generic and biosimilar medicines industry is specifically to promote
the widest possible access to affordable medicines with high quality, safety, and efficacy for
patients globally by introducing competition into the markets. Despite the many hurdles, the
generic medicines companies have clearly lived up to the challenges posed by the pandemic
as it is an industry that is quick to adapt and agile in manufacturing scale-up. During the
outbreak of COVID-19, this industry was providing most of the medicines needed in Intensive
Care Units to ventilate critically ill COVID patients. It is also providing most of the quality
medicines dispensed around the world, especially for increasingly prevalent chronic diseases
and is therefore a strong contributor to health outcomes globally.
whitePaper | April 7, 2021
In less than a week, in the face of a pandemic, the pharmaceutical sales model changed forever. In-person healthcare provider (HCP) visits came to a screeching halt and brand marketers scrambled to find ways to educate and engage these providers remotely. While the pandemic may have taken us by surprise, we should acknowledge that, even before the pandemic, pharmaceutical sales teams faced significant challenges.
One solution for these challenges is to engage HCPs – virtually.
whitePaper | April 1, 2021
Every year, the U.S. pharmaceutical industry develops
a variety of new drugs that provide valuable medical
benefits. Many of those drugs are expensive and contribute to rising health care costs for the private sector and
the federal government. Policymakers have considered
policies that would lower drug prices and reduce federal
drug expenditures. Such policies would probably reduce
the industry’s incentive to develop new drugs.
whitePaper | January 31, 2022
COVID-19 is an infectious disease caused by a newly discovered coronavirus, which was
first identified in December 2019.
whitePaper | April 8, 2020
EPHA is a change agent – Europe’s leading NGO alliance advocating for better health. We are a dynamic member-led organisation, made up of public health civil society, patient groups, health professionals, and disease groups working together to improve health and strengthen the voice of public health in Europe.
whitePaper | January 1, 2020
Life sciences is facing a number of disruptors: novel cell and gene therapies that will revolutionize manufacturing, drug delivery and pricing models; a battle for the best and brightest talent; political and public pressure on the price of medication as well as the implications of the fourth industrial revolution. These factors combine to make investment decisions more challenging. With life sciences firms placing an increasing focus on the most efficient use of capital and shorter delivery times, project delivery providers are striving to come up with leaner and more innovative strategies and solutions to meet these needs. Integrated Project Delivery (IPD) is one such strategy.
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the
community for FREE